05/07/2010Funding Opportunity Announcement

CHDI Foundation, Inc. (CHDI) and the National Institute of Neurological Disorders and Stroke (NINDS) have released a funding opportunity announcement (FOA) regarding an extramural program to preclinically validate therapeutic targets for Huntington's disease (HD). CHDI, a not-for-profit virtual biotech company that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of HD, will provide a $4.5 million gift to NINDS for "set aside" funds to support R01 research projects in addition to those financed within regular NINDS funding policies.

04/09/2010A Video Postcard from Charles Sabine

Charles Sabine has produced a video postcard from CHDI's 5th Annual Huntington's Disease Therapeutics Conference.

04/29/2010

Galapagos and CHDI Foundation, Inc. Enter New Five-Year Collaboration

Galapagos NV and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington's disease, announced today a new five-year collaboration focused on discovering novel drugs for Huntington's disease. Galapagos' service division BioFocus will perform the research and is eligible to receive US$41 million in research fees during the five-year collaboration.

04/20/2010

AMRI Extends Drug Discovery Collaboration with CHDI Foundation, Inc.

Albany, NY - AMRI announced today the five year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc., focused on the discovery of new therapeutic agents for the treatment of Huntington's disease.

04/14/2010

My Data, Your Data, Our Data

The Wall Street Journal writes about Sage Bionetworks and its efforts to build an open-source collaborative effort to compile scientific databases in order to build powerful disease models, including Huntington's disease.

Evotec and CHDI Foundation Extend Collaboration to Fight Huntington's Disease01/14/2010

Evotec AG today announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington's Disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, will provide Evotec with up to US$37.5 million in research funding over the next three years.

10/13/2009

Dotmatics has Licensed its Browser and Vortex Solutions to CHDI

Dotmatics Limited (Dotmatics), a leading provider of drug discovery informatics products and services, is pleased to announce they have been selected by CHDI Foundation, Inc. to provide scientific data management, data mining, and analysis solutions.

04/29/2009AMRI Commences Drug Discovery Collaboration

AMRI (NASDAQ: AMRI) and CHDI Foundation, Inc., a non-profit organization pursuing drugs that delay or slow Huntington’s disease (HD), announced today the commencement of a new collaboration agreement focused on the discovery of new therapeutic agents for the treatment of this disease.

02/27/2009GlobalStem and CHDI Foundation Sign Agreement

Partnership will provide researchers with fully-authenticated supply of single-mutant cell culture models of Huntington's disease.

10/29/2008Galapagos and CHDI Enter New Collaborations

Galapagos NV and CHDI Foundation, Inc. announced today new collaboration agreements focused on developing novel assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD. Total value of the contracts for Galapagos is $1 million (€0.8 million) over 1.5 years.

07/15/2008New Partnership with Ingenuity

Ingenuity Systems and CHDI announce multi-year deal for a disease-specific knowledge platform.

06/17/2008Vertex Establishes Collaboration with CHDI

Vertex establishes early-stage Huntington’s disease research collaboration with CHDI Foundation.

06/01/2008Removing Resource Barriers for HD Researchers

CHDI and the Coriell Institute for Medical Research have established the HD Community BioRepository for researchers investigating Huntington's disease.

05/01/2008

CHDI Foundation: A change in our name

May 1, 2008 – CHDI, Inc., recently renamed CHDI Foundation, Inc., and High Q Foundation, Inc. announced that CHDI has taken over primary responsibility for the types of Huntington’s disease research projects previously funded by High Q. CHDI will now be supporting the full gamut of Huntington’s disease research activities from basic discovery research through clinical development.